Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 40
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
2.
Int J Womens Dermatol ; 10(3): e181, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39281007

RESUMEN

Background: Alopecic sarcoidosis is an uncommon cutaneous manifestation of sarcoidosis. Scarring and nonscarring alopecic sarcoidosis have been reported; however, information on the epidemiology, systemic disease associations, and treatment efficacy is limited. Objective: To address these gaps, we conducted a retrospective chart review and systematic literature review of alopecic sarcoidosis cases. Methods: Full-text English publications from PubMed, Scopus, and Google Scholar from inception to August 2023 were analyzed. Treatment evidence quality was assessed using the modified Oxford Centre for Evidence-Based Medicine rating scale. Three patients with biopsy-proven alopecic sarcoidosis were included as a case series, all demonstrating systemic sarcoidosis and 2 requiring multiple therapies. Among 1778 search results, 60 articles representing 77 cases of alopecic and scalp sarcoidosis were included. Patients were categorized into 4 distinct alopecic subgroups. Black patients constituted the majority of all subgroups. Results: Extracutaneous sarcoidosis burden was high across all alopecic subgroups, with ocular disease appearing overrepresented. Topical and oral corticosteroids were the main treatments. Though scarring alopecia patients had poor outcomes despite receiving immunomodulators/cx, limited data suggest potential efficacy of tumor necrosis factor-alpha inhibitors. Limitations: This study has a small sample size. Conclusion: Our findings underscore the importance of evidence-based strategies for improving alopecic sarcoidosis management. Prompt diagnosis and systemic evaluation, especially for scarring alopecia, are essential for timely intervention to optimize patient outcomes.

5.
Arch Dermatol Res ; 316(9): 622, 2024 Sep 14.
Artículo en Inglés | MEDLINE | ID: mdl-39276230

RESUMEN

LDOM has enhanced treatment options for female AGA, yet its combined efficacy with therapies such as spironolactone, finasteride, or dutasteride remains inadequately explored. This study aims to compare the efficacy and safety of LDOM in combination with spironolactone versus LDOM with finasteride or dutasteride in women with AGA. Our analysis revealed that both combination therapies produced similar improvements in hair growth and had comparable safety profiles. Although the LDOM with finasteride/dutasteride group showed a greater average increase in hair width and density, these differences were not statistically significant. These results endorse the use of LDOM in combination with either spironolactone or finasteride/dutasteride for female AGA, and underscore the necessity for further research to validate these findings and assess long-term treatment outcomes.


Asunto(s)
Alopecia , Quimioterapia Combinada , Dutasterida , Finasterida , Minoxidil , Espironolactona , Humanos , Femenino , Finasterida/administración & dosificación , Dutasterida/administración & dosificación , Espironolactona/administración & dosificación , Alopecia/tratamiento farmacológico , Minoxidil/administración & dosificación , Adulto , Resultado del Tratamiento , Quimioterapia Combinada/métodos , Persona de Mediana Edad , Inhibidores de 5-alfa-Reductasa/administración & dosificación , Administración Oral , Cabello/efectos de los fármacos , Cabello/crecimiento & desarrollo , Adulto Joven , Estudios Retrospectivos
6.
Arch Dermatol Res ; 316(8): 514, 2024 Aug 12.
Artículo en Inglés | MEDLINE | ID: mdl-39133308

RESUMEN

Androgenetic alopecia (AGA) significantly impacts patients' psychological well-being, and treatment options have historically been limited. However, the advent of low-dose oral minoxidil (LDOM) has revolutionized AGA management. This study compares the treatment response and safety of LDOM in patients with AGA alone versus those with AGA unmasked by telogen effluvium. Our findings indicate that LDOM is effective and safe for both groups, showing comparable efficacy and safety profiles. These results support the use of LDOM as a reliable treatment option for AGA, potentially improving patient outcomes and quality of life.


Asunto(s)
Alopecia , Minoxidil , Humanos , Minoxidil/administración & dosificación , Femenino , Adulto , Alopecia/tratamiento farmacológico , Administración Oral , Masculino , Resultado del Tratamiento , Persona de Mediana Edad , Calidad de Vida , Adulto Joven
10.
Cureus ; 16(6): e63120, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-39055467

RESUMEN

Alopecia areata (AA) has long been considered a challenging clinical condition, with dermatologists traditionally employing corticosteroids and immunosuppressants in search of effective solutions. The introduction of Janus kinase inhibitors (JAKi), specifically the Food and Drug Administration (FDA) approval of baricitinib, marked a significant breakthrough in the treatment of AA. Clinical trials have shown promising results with baricitinib, and reports of relapse after initial success are scarce. We present a unique case of a 30-year-old male with severe patch-type AA who initially responded well to baricitinib treatment but later experienced a relapse despite continued treatment.

12.
Int J Dermatol ; 63(9): 1128-1130, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38741261

RESUMEN

The widespread adoption of glucagon-like peptide-1 (GLP-1) agonists in treating type 2 diabetes mellitus (T2DM) and obesity has sparked investigations into their impact on hair health, an area characterized by diverse conjectures. Some propose potential risks such as disrupted hair growth cycles or premature androgenetic alopecia (AGA), while others suggest benefits linked to improved insulin sensitivity and enhanced scalp blood circulation. However, despite these theoretical underpinnings, clinical evidence linking GLP-1 agonists to hair loss remains sparse. The necessity for vigilant patient monitoring and collaborative efforts cannot be overstressed in comprehensively addressing any potential consequences of GLP-1 agonist therapy on hair health as their use continues to expand.


Asunto(s)
Alopecia , Diabetes Mellitus Tipo 2 , Péptido 1 Similar al Glucagón , Hipoglucemiantes , Humanos , Alopecia/tratamiento farmacológico , Péptido 1 Similar al Glucagón/agonistas , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Hipoglucemiantes/efectos adversos , Obesidad/tratamiento farmacológico , Resistencia a la Insulina , Cuero Cabelludo , Cabello/crecimiento & desarrollo , Cabello/efectos de los fármacos
15.
Cureus ; 16(4): e58830, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38784309

RESUMEN

Keratosis pilaris atrophicans faciei (KPAF) and frontal fibrosing alopecia (FFA) present diagnostic challenges due to their similar clinical characteristics. Dermatologists often employ overlapping treatment regimens, which may hinder accurate diagnosis and treatment expectations. Genetic testing offers promise for precise diagnosis and tailored treatment strategies, yet its utility in these conditions remains underexplored. This manuscript presents a unique case study of a 36-year-old male with symptoms of both KPAF and FFA, who underwent genetic testing. Despite testing negative for this mutation, the case underscores the potential of genetic testing to enhance diagnostic accuracy and optimize treatment outcomes.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...